
This retrospective study was designed to evaluate possible relationships between the number and types of zzso medications administered to patients on the first day of therapy in phase I trials and demographic zzso outcome measures and zzso zzso medications received by zzso patients enrolled on 28 phase I trials between August 1985 and January 1996 were grouped into 31 categories based on the American Hospital zzso Service zzso These patients received 1650 cycles of treatment with zzso agents zzso 2 cycles per zzso Median duration zzso was 49 days zzso zzso zzso Clinical response rate zzso zzso zzso was zzso Only three toxic deaths occurred zzso Nearly all patients zzso received at least one zzso medication on the first day of zzso The number of zzso medications directly correlated with poor performance status zzso zzso zzso p zzso zzso and indirectly with duration zzso zzso zzso zzso p zzso zzso The dose of the zzso agent administered during the first course of therapy was not related to zzso medications on the first day of zzso Most importantly, no relationships were observed between zzso medications and either zzso or clinical response to zzso We conclude that patients who are receiving zzso medications should not systematically be excluded from phase I zzso 

